Medscape12d
Vedolizumab Beats Infliximab as Second-Line Therapy for Ulcerative Colitis
In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...
Hosted on MSN2mon
Vedolizumab Edges Out Infliximab for Ulcerative Colitis in Real-World Study
ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...
Medpage Today on MSN2mon
Vedolizumab Maintenance Safe and Effective for Kids With IBD
Maintenance treatment with vedolizumab (Entyvio) appeared to be safe and effective in children with inflammatory bowel ...
National Institute for Health and Care Excellence4d
Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]
Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...
Medindia8d
Vedolizumab Outperforms Infliximab in Second-Line Therapy for Ulcerative Colitis
Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...